- Conditions
- Liver Metastases, Colon Cancer
- Interventions
- Dynamic contrast-enhanced ultrasound imaging, Optical Tracking Device, Electromagnetic Tracking Device, Perflutren
- Procedure · Device · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Stanford, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Covid19, Multisystem Inflammatory Syndrome in Children (MIS-C)
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Minute to 17 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Speech Sound Disorder
- Interventions
- Biofeedback-ultrasound, Biofeedback--visual-acoustic, Traditional articulation treatment
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 9 Years to 15 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Bloomfield, New Jersey • Syracuse, New York
- Conditions
- Speech Sound Disorder
- Interventions
- Visual-acoustic biofeedback, Ultrasound biofeedback
- Behavioral
- Lead sponsor
- New York University
- Other
- Eligibility
- 9 Years to 15 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 3
- States / cities
- Bloomfield, New Jersey • New York, New York • Syracuse, New York
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- Sonobiopsy, Research blood, Cancer Personalized Profiling, Definity®
- Device · Procedure · Genetic
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Proliferative Breast Disease
- Interventions
- Contrast Enhanced imaging, Lumason
- Diagnostic Test · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Liver Cirrhosis
- Interventions
- Dynamic Contrast-Enhanced Ultrasound Imaging
- Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 612 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- San Diego, California • Philadelphia, Pennsylvania • Nashville, Tennessee + 2 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Perflutren Lipid Microspheres, Sulfur Hexafluoride Lipid Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging, Positron Emission Tomography, Computed Tomography, Yttrium-90 (90Y)
- Drug · Device · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Gorham Disease, Lymphatic Diseases, Lymphangiomatosis
- Interventions
- Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL), Heavy Weighted T2 Imaging (T2W), Lymph Node Access
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 2 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Solid Tumor, Lymphomas
- Interventions
- RRx-001
- Drug
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- La Jolla, California • Nashville, Tennessee
- Conditions
- Renal Cell Carcinoma
- Interventions
- Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- dynamic contrast-enhanced ultrasound imaging, shear wave elastography, Definity, (Lipid Microspheres) Intravenous Suspension, Philips Shear Wave Elastography
- Procedure · Drug · Device
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Necrotizing Enterocolitis of Newborn, Bowel Ischemic
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib, DCE-MRI and Quantitative Doppler Ultrasound
- Drug · Device
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer
- Interventions
- filgrastim, capecitabine, celecoxib, cyclophosphamide, docetaxel, doxorubicin hydrochloride, gene expression analysis, polymorphism analysis, protein expression analysis, reverse transcriptase-polymerase chain reaction, imaging biomarker analysis, immunohistochemistry staining method, laboratory biomarker analysis, pharmacogenomic studies, dynamic contrast-enhanced magnetic resonance imaging, needle biopsy, neoadjuvant therapy, radiomammography, ultrasound imaging
- Biological · Drug · Genetic + 2 more
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years to 120 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging
- Drug · Other · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Yttrium-90 Microsphere Radioembolization, Perflutren Protein-Type A Microspheres, Dynamic Contrast-Enhanced Ultrasound Imaging
- Procedure · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania